Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.45 |
| ▸ | IDH1 | O75874 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766536 | 0.85 | HDAC1 (0.52) | RORCLMNAMGAT2MCL1HPGD | |
| SCHEMBL6574032 | 0.83 | HIF1A (0.43) | RORCIDH1LMNAMGAT2MCL1 | |
| SCHEMBL6574325 | 0.81 | LMNA (0.44) | RORCIDH1IDO1LMNAALDH1A1 | |
| SCHEMBL6571783 | 0.80 | LMNA (0.51) | RORCIDH1IDO1LMNAMGAT2 | |
| SCHEMBL6765129 | 0.79 | MGAT2 (0.56) | RORCLMNAMGAT2ALDH1A1HPGD | |
| SCHEMBL6572898 | 0.79 | IDH1 (0.40) | RORCIDH1IDO1LMNAALDH1A1 | |
| SCHEMBL6762133 | 0.77 | POLB (0.53) | RORCLMNAMCL1ALDH1A1HPGD | |
| SCHEMBL6766083 | 0.76 | HDAC1 (0.51) | RORCIDO1LMNAMCL1 | |
| SCHEMBL6571948 | 0.74 | HDAC1 (0.48) | RORCIDO1LMNAMCL1ALDH1A1 | |
| SCHEMBL6570560 | 0.74 | F2 (0.45) | RORCIDO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1414790-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003000653-A1 | SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | RORC 1596/4885IDH1 602/4885IDO1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.